Alessandro Catanese

Alessandro Catanese

Auto-generated profile, based on publicly available information

Alessandro Catanese

Unitat de Diagnòstic per la Imatge de la Mama (UDIM), Hospital Germans Trias i Pujol, Badalona, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Scientific Data
Verified
Journal Article
Open access
PDF file
LGLidia Garrucho
Lidia Garrucho
KKKaisar Kushibar
Kaisar Kushibar
CRClaire-Anne Reidel
Claire-Anne Reidel
SJSmriti Joshi
Smriti Joshi
RORichard Osuala
Richard Osuala
KLKarim Lekadir
Karim Lekadir
Artificial Intelligence (AI) research in breast cancer Magnetic Resonance Imaging (MRI) faces challenges due to limited expert-labeled segmentations. To address this, we present a multicenter dataset of 1506 pre-treatment T1-weighted dynamic contrast-enhanced MRI cases, including expert annotations of primary tumors and non-mass-enhanced regions. The dataset integrates imaging data from four collections in The Cancer Imaging Archive (TCIA), where only 163 cases with expert segmentations were initially available. To facilitate the annotation process, a deep learning model was trained to produce preliminary segmentations for the remaining cases. These were subsequently corrected and verified by 16 breast cancer experts (averaging 9 years of experience), creating a fully annotated dataset. Additionally, the dataset includes 49 harmonized clinical and demographic variables, as well as pre-trained weights for a baseline nnU-Net model trained on the annotated data. This resource addresses a critical gap in publicly available breast cancer datasets, enabling the development, validation, and benchmarking of advanced deep learning models, thus driving progress in breast cancer diagnostics, treatment response prediction, and personalized care.

1 March 2021 in Surgical Oncology
Verified
Journal Article
Closed access
AMAntonio Mariscal Martínez
Antonio Mariscal Martínez
IRIrene Vives Roselló
Irene Vives Roselló
AGAngela Salazar Gómez
Angela Salazar Gómez
ACAlessandro Catanese
Alessandro Catanese
MMMariola Pérez Molina
Mariola Pérez Molina
MTMiguel Angel Luna Tomás
Miguel Angel Luna Tomás

23 June 2017 in The Neuroradiology Journal
Verified
Journal Article
Closed access
ACA Catanese
A Catanese
FMF Malacario
F Malacario
LCLuigi Cirillo
Luigi Cirillo
FTF Toni
F Toni
CZC Zenesini
C Zenesini
RAR Agati
R Agati
Intravoxel incoherent motion is a potential non-invasive diagnostic tool in brain tumours, without any clear guidelines for its evaluation yet. In our study, we compare intravoxel incoherent motion with dynamic susceptibility contrast magnetic resonance imaging in the quantification of tumour tissue blood perfusion in 28 patients affected by brain tumours, highlighting the issues encountered during the acquisition set-up and post-processing steps. Intravoxel incoherent motion is a new imaging tool and an alternative technique to dynamic susceptibility contrast-magnetic resonance imaging which is of considerable interest at present. This is partly because it does not require the use of a contrast agent and relies on the intrinsic properties of motion in the capillaries of the spins. Compared to dynamic susceptibility contrast-magnetic resonance imaging, the intravoxel incoherent motion technique is also characterised by better resolution because the gadolinium-based contrast agent bolus used in the standard technique results in a variation by more than 50% of the signal coming from the brain. Finally, intravoxel incoherent motion is more sensitive to the incoherent motion that originates from small capillary vessels, while the dynamic susceptibility contrast signal is also contaminated by the input from larger arteries and veins, which may result in an overestimation of the blood volume. Although there are limitations due to the heterogeneity of the sample considered in our study, intravoxel incoherent motion has been shown to be an accurate noninvasive radiological biomarker, useful to distinguish between low and high grade glial tumours.